key: cord-0932371-m4lv4g4b
authors: Czeisler, Mark É.; Rajaratnam, Shantha M.W.; Howard, Mark E.; Czeisler, Charles A.
title: Accommodating vaccine preferences among women of childbearing age
date: 2021-07-31
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.07.017
sha: 23e5b82b383f7a1ab62191154635b32ba3b48a55
doc_id: 932371
cord_uid: m4lv4g4b

nan

Accommodating vaccine preferences among women of childbearing age TO THE EDITORS: After pregnant persons were excluded from the initial trials leading to emergency use authorizations for COVID-19 vaccines in the United States, Gray et al 1 demonstrated robust vaccine-induced immune responses among pregnant women following COVID-19 messenger RNA (mRNA) vaccination (Pfizer-BioNTech and Moderna), with placental and breastmilk immune transfer to neonates. Unfortunately, rare clotting events following Janssen and AstraZeneca COVID-19 vaccination, which have been disproportionately experienced by women of childbearing age, have dampened the enthusiasm for these vaccines. At present, tailored education and vaccine deployment efforts should prioritize pregnant persons to mitigate newly recognized maternal and neonatal health risks following SARS-CoV-2 infection. 2 Moreover, given the fundamental principles of self-determination, personhood, and patient autonomy that underlie informed consent, respecting patients' right to make voluntary and informed healthcare decisions requires that all individuals should be fully informed about the risks and benefits of each vaccine, and-if feasible-provided a choice among the available COVID-19 vaccines.

Improving vaccine uptake among pregnant women is of heightened importance given recent evidence that pregnant women with SARS-CoV-2 infection have a considerably elevated risk of adverse maternal and neonatal health outcomes, including 22 times the risk of maternal mortality and twice the risk of both severe neonatal morbidity and perinatal morbidity and mortality than do pregnant women without SARS-CoV-2 infection. 2 Reassuringly, we found that 70% of surveyed pregnant women in the United States would definitely or most likely obtain a COVID-19 vaccine as soon as possible. 3 Understandably, the initial phase of the US vaccine rollout did not accommodate personal preferences among COVID-19 vaccines. However, in contrast to other countries with inadequate vaccine supplies or only 1 available vaccine, in the United States, 3 different COVID-19 vaccines are currently in supply that now exceeds demand because of vaccine hesitancy and apathy. With newfound evidence of maternal and neonatal protection conferred by mRNA vaccines, 1 increased risk of adverse health outcomes associated with SARS-CoV-2 infection among pregnant women, 2 and disproportionate Janssen and AstraZeneca vaccine side effects among women of childbearing age, we strongly disagree with the recent suggestion that "health systems . . . should communicate to patients that they will receive, and only really need, one choice of vaccine." 4 We believe that amid this public health crisis, these considerations necessitate that women of childbearing age be afforded a choice among COVID-19 vaccines to reduce elevated adverse vaccination side effects experienced by women of childbearing age, vaccine hesitancy, and the serious risks COVID-19 poses for pregnant women and their children. 2 

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study

Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study

COVID-19 vaccine intentions in the United States

Choices in a crisis-individual preferences among SARS-CoV-2 vaccines

All rights reserved

All authors report institutional grants to Monash University from the CDC Foundation, with funding from Bank of New York Mellon, and from WHOOP, Inc., as well as a gift from Hopelab, Inc. M.É.C. reported receiving grants from the Fulbright Foundation sponsored by The Kinghorn Foundation and personal fees from Vanda Pharmaceuticals Inc. S.M.W.R. reported receiving grants and personal fees from the Cooperative Research Centre for Alertness, Safety and Productivity, grants and institutional consultancy fees from Teva Pharma Australia, and institutional consultancy fees from Vanda Pharmaceuticals Inc, Circadian Therapeutics, BHP Billiton, and Herbert Smith Freehills. C.A.C. reported receiving grants and personal fees from Teva Pharma Australia; grants from the National Institute of Occupational Safety and Health (R01-OH-011773); personal fees from and equity interest in Vanda Pharmaceuticals Inc; educational and research support from Philips Respironics Inc; an endowed professorship provided to Harvard Medical School from Cephalon, Inc; an institutional gift from Alexandra Drane; and a patent on Actiwatch-2 and Actiwatch-Spectrum devices with royalties paid from Philips Respironics Inc. C.A.C.'s interests were reviewed and managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. In addition, C.A.C. served as a voluntary board member for the Institute for Experimental Psychiatry Research Foundation, Inc.No direct funding was provided for this Letter to the Editors. M.É.C. was supported by an Australian-American Fulbright Scholarship, with funding from The Kinghorn Foundation. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.